FLASH NEWS LIVE

US Stocks: Biogen gets FDA approval for higher dose of genetic disorder drug, shares rise 3%

US Stocks: Biogen gets FDA approval for higher dose of genetic disorder drug, shares rise 3%

The U.S. Food and Drug Administration has approved a higher dose of Biogen's spinal muscular atrophy ‌drug Spinraza, ⁠the company ⁠said on Monday, after rejecting it last year.

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
Instagram Meta X LinkedIn Whatsapp